SOURCE: Generex Biotechnology

May 12, 2006 07:30 ET

Generex Biotechnology Subsidiary Presents Avian Influenza Vaccine Program at Embassy Briefing in Washington, D.C.

TORONTO -- (MARKET WIRE) -- May 12, 2006 -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that Dr. Eric von Hofe, the President of Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, made an invited presentation this week of the Company's synthetic avian influenza program at an embassy briefing hosted by Sandler, Travis & Rosenberg, P.A. in Washington, D.C.

The purpose of the briefing was to update delegates from the embassies of approximately 35 countries on the potential for an outbreak of pandemic avian influenza and preparations undertaken by the United States government to prepare for such an event.

Dr. von Hofe participated in the briefing as a member of a panel of experts on efforts to develop a widely available vaccine for avian influenza. The only H5N1 vaccines currently available must be given in very high doses and are available in very limited quantities. Antigen Express is developing a vaccine that can be manufactured by entirely synthetic means, in large amounts, rapidly, and at lower cost. The Company is currently conducting late-stage pre-clinical studies on the vaccine and has been in discussions with the United Stated Food and Drug Administration in respect of preparations for the filing of an Investigation New Drug Application for the vaccine.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex website at or the Antigen Express website at

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact Information

  • Contact:
    Shayne Gilliatt
    Generex Biotechnology Corporation
    Phone: (800) 391-6755 and (416) 364-2551

    Andrew Hellman
    CEOcast, Inc.
    Phone: 1 (212) 732-4300